Randall J. Bateman

2 months ago | nature.com | Jorge J. Llibre-Guerra |Nelly Joseph-Mathurin |Kathleen Carter |Eric McDade |Brian Gordon |Alan E. Renton | +8 more

AbstractWe conducted an in-depth longitudinal study on an individual carrying the presenilin 2 p.Asn141Ile mutation, traditionally associated with dominantly inherited Alzheimer’s disease (AD), who has remarkably remained asymptomatic past the expected age of clinical onset. This study combines genetic, neuroimaging and biomarker analyses to explore the underpinnings of this resilience.

Nov 17, 2024 | nature.com | Stephan A. Kaeser |Christian la Fougère |Jonathan Voglein |Johannes Levin |Nick Fox |Henrik Zetterberg | +16 more

AbstractDisease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes.

Nov 17, 2024 | nature.com | Stephan A. Kaeser |Christian la Fougère |Jonathan Voglein |Johannes Levin |Nick Fox |Henrik Zetterberg | +16 more

AbstractDisease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes.

Oct 8, 2024 | nature.com | Agustín Ibáñez |Randall J. Bateman

A trailblazing Latin American leader in Alzheimer’s disease research and a compassionate patient advocate Francisco Lopera, a groundbreaking neurologist who undertook pioneering work in early-onset Alzheimer’s disease (EOAD), passed away on 10 September 2024. He revolutionized the field of Alzheimer’s disease research and was the recipient of several recognitions, including the Potamkin Prize and the Bengt Winblad Lifetime Achievement Award.

Jul 2, 2024 | nature.com | Jingqin Luo |Erik D. Roberson |Carlos Cruchaga |David M. Holtzman |Randall J. Bateman

AbstractBlood-based biomarkers of Alzheimer disease (AD) may facilitate testing of historically under-represented groups. The Study of Race to Understand Alzheimer Biomarkers (SORTOUT-AB) is a multi-center longitudinal study to compare AD biomarkers in participants who identify their race as either Black or white. Plasma samples from 324 Black and 1,547 white participants underwent analysis with C2N Diagnostics’ PrecivityAD test for Aβ42 and Aβ40.